Lin Shen
YOU?
Author Swipe
View article: 12kW@2K Helium Cryogenic Control System Design
12kW@2K Helium Cryogenic Control System Design Open
This paper presents the design and implementation of a 12kW@2K supercritical helium cryogenic control system for the Shanghai Hard X-ray Free Electron Laser Facility (SHINE). The system provides a stable cryogenic environment for 56 standa…
View article: 12kW@2K Helium Cryogenic Control System Design and Implementation
12kW@2K Helium Cryogenic Control System Design and Implementation Open
This paper presents the design and implementation of a 12kW@2K supercritical helium cryogenic control system for the Shanghai Hard X-ray Free Electron Laser Facility (SHINE). The system provides a stable cryogenic environment for 56 standa…
View article: Nab-paclitaxel plus bevacizumab for patients with metastatic extrapulmonary neuroendocrine carcinoma: a phase 2 single-arm study
Nab-paclitaxel plus bevacizumab for patients with metastatic extrapulmonary neuroendocrine carcinoma: a phase 2 single-arm study Open
This study was partially supported by Qilu Pharmaceutical Co., Ltd. This work is supported by the Beijing Municipal Science & Technology Commission (No. Z231100007223002).
View article: Efficacy and safety of glecirasib in solid tumors with <i>KRAS</i> G12C mutation: A pooled analysis of two phase I/II trials
Efficacy and safety of glecirasib in solid tumors with <i>KRAS</i> G12C mutation: A pooled analysis of two phase I/II trials Open
Background Glecirasib, an inhibitor of Kirsten rat sarcoma viral oncogene homolog glycine‐to‐cysteine substitution at codon 12 ( KRAS G12C), has exhibited clinical activity in non‐small‐cell lung cancer (NSCLC) and colorectal cancer (CRC).…
View article: Vi-SAFE: A Spatial-Temporal Framework for Efficient Violence Detection in Public Surveillance
Vi-SAFE: A Spatial-Temporal Framework for Efficient Violence Detection in Public Surveillance Open
Violence detection in public surveillance is critical for public safety. This study addresses challenges such as small-scale targets, complex environments, and real-time temporal analysis. We propose Vi-SAFE, a spatial-temporal framework t…
View article: Reply to: “ <i>NOTCH1</i> : A Potential New Biomarker in the Era of Immunotherapy?” and “Caution in Interpreting <i>NOTCH1</i> Mutation as a Predictive Biomarker of Tislelizumab Response in Esophageal Squamous Cell Carcinoma”
Reply to: “ <i>NOTCH1</i> : A Potential New Biomarker in the Era of Immunotherapy?” and “Caution in Interpreting <i>NOTCH1</i> Mutation as a Predictive Biomarker of Tislelizumab Response in Esophageal Squamous Cell Carcinoma” Open
View article: Trastuzumab deruxtecan in patients from China with previously treated human epidermal growth factor receptor 2–positive locally advanced/metastatic gastric or gastroesophageal junction adenocarcinoma (DESTINY-Gastric06): results from a single-arm, multicenter, phase 2 trial
Trastuzumab deruxtecan in patients from China with previously treated human epidermal growth factor receptor 2–positive locally advanced/metastatic gastric or gastroesophageal junction adenocarcinoma (DESTINY-Gastric06): results from a single-arm, multicenter, phase 2 trial Open
AstraZeneca.
View article: Tasurgratinib (E7090) for cholangiocarcinoma with fibroblast growth factor receptor 2 fusions/rearrangements: a multicenter, open-label, Phase 2 study
Tasurgratinib (E7090) for cholangiocarcinoma with fibroblast growth factor receptor 2 fusions/rearrangements: a multicenter, open-label, Phase 2 study Open
Background This Phase 2 study (NCT04238715) evaluated the efficacy/safety of tasurgratinib 140 mg daily in patients with cholangiocarcinoma (CCA) and fibroblast growth factor receptor (FGFR) 2 fusions/rearrangements. Methods Eligible Japan…
View article: Comparison of efficacy and safety of combined phacoemulsification, goniosynechialysis and goniotomy with trabeculectomy in advanced primary angle-closure glaucoma: a retrospective observational study
Comparison of efficacy and safety of combined phacoemulsification, goniosynechialysis and goniotomy with trabeculectomy in advanced primary angle-closure glaucoma: a retrospective observational study Open
Purpose The study is a retrospective observational study. This study aimed to compare the intraocular pressure (IOP) lowering effect of phacoemulsification combined with intraocular lens implantation (PEI), Goniosynechialysis (GSL), and go…
View article: CLDN18.2–targeting antibody–drug conjugate IBI343 in advanced gastric or gastroesophageal junction adenocarcinoma: a phase 1 trial
CLDN18.2–targeting antibody–drug conjugate IBI343 in advanced gastric or gastroesophageal junction adenocarcinoma: a phase 1 trial Open
Aberrant expression of claudin18.2 (CLDN18.2) has frequently been observed in gastric and gastroesophageal junction (G/GEJ) adenocarcinoma, making it a promising therapeutic target for this aggressive cancer. While a monoclonal antibody ta…
View article: Fruquintinib in less pretreated patients: Multivariate profile-matching analysis of FRESCO-2 to FRESCO
Fruquintinib in less pretreated patients: Multivariate profile-matching analysis of FRESCO-2 to FRESCO Open
Clinically meaningful efficacy of fruquintinib was maintained in a global patient population with less pretreated mCRC than the FRESCO-2 ITT population, with no new safety signals, demonstrating efficacy regardless of prior treatment lines.
View article: A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors
A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors Open
Purpose: Givastomig is a bispecific antibody that targets CLDN18.2 and conditionally activates local 4-1BB–expressing T cells. This first-in-human study evaluated the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor …
View article: Supplementary Table S5 from Safety and Efficacy of KN046 in Combination with KN026 in Patients with Advanced HER2-Positive Breast Cancer: A Phase II Trial
Supplementary Table S5 from Safety and Efficacy of KN046 in Combination with KN026 in Patients with Advanced HER2-Positive Breast Cancer: A Phase II Trial Open
Supplemental table 5 Anti-HER2 treatment-related adverse events in patients
View article: Supplementary Table S4 from Safety and Efficacy of KN046 in Combination with KN026 in Patients with Advanced HER2-Positive Breast Cancer: A Phase II Trial
Supplementary Table S4 from Safety and Efficacy of KN046 in Combination with KN026 in Patients with Advanced HER2-Positive Breast Cancer: A Phase II Trial Open
Supplemental table 4 Immune-related adverse events (irAEs) in patients
View article: Supplementary Data S1 from Safety and Efficacy of KN046 in Combination with KN026 in Patients with Advanced HER2-Positive Breast Cancer: A Phase II Trial
Supplementary Data S1 from Safety and Efficacy of KN046 in Combination with KN026 in Patients with Advanced HER2-Positive Breast Cancer: A Phase II Trial Open
Trial protocol
View article: Data from Safety and Efficacy of KN046 in Combination with KN026 in Patients with Advanced HER2-Positive Breast Cancer: A Phase II Trial
Data from Safety and Efficacy of KN046 in Combination with KN026 in Patients with Advanced HER2-Positive Breast Cancer: A Phase II Trial Open
Purpose:In this study, we report the results from a phase II trial assessing the safety and efficacy of KN046 in combination with KN026 in patients with HER2-positive metastatic breast cancer, who had progressed after prior anti-HER2 combi…
View article: Supplementary Table S1 from Safety and Efficacy of KN046 in Combination with KN026 in Patients with Advanced HER2-Positive Breast Cancer: A Phase II Trial
Supplementary Table S1 from Safety and Efficacy of KN046 in Combination with KN026 in Patients with Advanced HER2-Positive Breast Cancer: A Phase II Trial Open
Supplemental table 1 Representativeness of study participants
View article: Supplementary Table S3 from Safety and Efficacy of KN046 in Combination with KN026 in Patients with Advanced HER2-Positive Breast Cancer: A Phase II Trial
Supplementary Table S3 from Safety and Efficacy of KN046 in Combination with KN026 in Patients with Advanced HER2-Positive Breast Cancer: A Phase II Trial Open
Supplemental table 3 Summary of the numbers of treatment discontinuations.
View article: Supplementary Table S2 from Safety and Efficacy of KN046 in Combination with KN026 in Patients with Advanced HER2-Positive Breast Cancer: A Phase II Trial
Supplementary Table S2 from Safety and Efficacy of KN046 in Combination with KN026 in Patients with Advanced HER2-Positive Breast Cancer: A Phase II Trial Open
Supplemental table 2 Sample size calculation.
View article: Tumor suppressor SLC9A2 inhibits colorectal cancer metastasis and reverses immunotherapy resistance by suppressing angiogenesis
Tumor suppressor SLC9A2 inhibits colorectal cancer metastasis and reverses immunotherapy resistance by suppressing angiogenesis Open
View article: 818 | INTERIM ANALYSIS OF POMALIDOMIDE PLUS RITUXIMAB, IFOSFAMIDE, CARBOPLATIN, AND ETOPOSIDE IN RELAPSED/REFRACTORY DLBCL: A PHASE I/II STUDY (PRIDE STUDY)
818 | INTERIM ANALYSIS OF POMALIDOMIDE PLUS RITUXIMAB, IFOSFAMIDE, CARBOPLATIN, AND ETOPOSIDE IN RELAPSED/REFRACTORY DLBCL: A PHASE I/II STUDY (PRIDE STUDY) Open
View article: Emerging Strategies of Cell and Gene Therapy Targeting Tumor Immune Microenvironment
Emerging Strategies of Cell and Gene Therapy Targeting Tumor Immune Microenvironment Open
Immunotherapy has profoundly transformed the landscape of cancer treatment and offered therapeutic opportunities to reverse the immunosuppressive microenvironment. However, intratumoral heterogeneity and the evolution toward immune evasion…
View article: Safety and Efficacy of KN046 in Combination with KN026 in Patients with Advanced HER2-Positive Breast Cancer: A Phase II Trial
Safety and Efficacy of KN046 in Combination with KN026 in Patients with Advanced HER2-Positive Breast Cancer: A Phase II Trial Open
Purpose: In this study, we report the results from a phase II trial assessing the safety and efficacy of KN046 in combination with KN026 in patients with HER2-positive metastatic breast cancer, who had progressed after prior anti-HER2 comb…
View article: Supplementary Figure S1 from Absolute Risk Prediction for Esophageal Squamous Cell Carcinoma Adaptable to Regional Disease Burden across Diverse Regions
Supplementary Figure S1 from Absolute Risk Prediction for Esophageal Squamous Cell Carcinoma Adaptable to Regional Disease Burden across Diverse Regions Open
Figure S1 showed that Area under the curve (AUC) analysis demonstrating the predictive performance across risk factors including gender, meal patterns, eating habits, family history, and BMI.
View article: Supplementary Figure S2 from Absolute Risk Prediction for Esophageal Squamous Cell Carcinoma Adaptable to Regional Disease Burden across Diverse Regions
Supplementary Figure S2 from Absolute Risk Prediction for Esophageal Squamous Cell Carcinoma Adaptable to Regional Disease Burden across Diverse Regions Open
Figure S2 showed that model calibration assessment comparing predicted risks against actual observed risks at 5-year and 10-year for control arm.
View article: Supplementary Table S3 from Absolute Risk Prediction for Esophageal Squamous Cell Carcinoma Adaptable to Regional Disease Burden across Diverse Regions
Supplementary Table S3 from Absolute Risk Prediction for Esophageal Squamous Cell Carcinoma Adaptable to Regional Disease Burden across Diverse Regions Open
Table S3 showed that the all-cause mortality excluding ESCC of Hua County
View article: Supplementary Table S1 from Absolute Risk Prediction for Esophageal Squamous Cell Carcinoma Adaptable to Regional Disease Burden across Diverse Regions
Supplementary Table S1 from Absolute Risk Prediction for Esophageal Squamous Cell Carcinoma Adaptable to Regional Disease Burden across Diverse Regions Open
Table S1 showed the crude odds ratios and p value of all the evaluated risk factors for ESCC
View article: <i>NOTCH1</i> Mutation and Survival Analysis of Tislelizumab in Advanced or Metastatic Esophageal Squamous Cell Carcinoma: A Biomarker Analysis From the Randomized, Phase III, RATIONALE-302 Trial
<i>NOTCH1</i> Mutation and Survival Analysis of Tislelizumab in Advanced or Metastatic Esophageal Squamous Cell Carcinoma: A Biomarker Analysis From the Randomized, Phase III, RATIONALE-302 Trial Open
PURPOSE Although multiple agents targeting PD-1 have been approved as second-line treatment for esophageal squamous cell carcinoma (ESCC), only a fraction of patients derive long-term survival. Hence, reliable predictive biomarkers are urg…
View article: Supplementary Methods from Absolute Risk Prediction for Esophageal Squamous Cell Carcinoma Adaptable to Regional Disease Burden across Diverse Regions
Supplementary Methods from Absolute Risk Prediction for Esophageal Squamous Cell Carcinoma Adaptable to Regional Disease Burden across Diverse Regions Open
The Supplementary Materials and Methods showed the inclusion criteria and questionnaire information collected in the ESECC trial and the definition and coding form for each candidate predictor evaluated in this study
View article: Data from Absolute Risk Prediction for Esophageal Squamous Cell Carcinoma Adaptable to Regional Disease Burden across Diverse Regions
Data from Absolute Risk Prediction for Esophageal Squamous Cell Carcinoma Adaptable to Regional Disease Burden across Diverse Regions Open
Background:Esophageal squamous cell carcinoma (ESCC) exhibits a long latency period and has a significant geographic disparity in incidence, which underscores the need for models predicting the long-term absolute risk adaptable to the regi…